Novel Inhaled Nitric Oxide (iNO) Therapy Delivery Through a Neonatal Transport HIgh Frequency Percussive Flow Ventilator (HFPFV)

Background: Sick neonates may require transport high frequency ventilation (HFV) with inhaled nitric oxide (iNO). Hospital based HFV-iNO systems are not transport capable. The neonatal transport HFPFV (Percussionaire, Sandpoint, ID) and the AeroNOx iNO system (International Biomedical, Austin, TX) are transport capable. The iNOmaxDSIR iNO system (Mallinckrodt Pharmaceuticals, Bedminster, NJ) is not approved with HFPFV. In-line iNOMaxDSIR alters the HFPFV clinical performance. One iNO delivery system for intra- and inter-hospital use has advantages: (1) lower costs and (2) single system maintenance. Primary Hypothesis: Effective iNO delivery can be achieved using side-stream iNOmaxDSIR injection into HFPFV. Secondary Hypothesis: The side-stream delivery will not clinically alter …